AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28698916 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ‐LNS during pregnancy and for 6 months postpartum
Number of subjects: 1151
Study 28698916 — intervention group
Group type: COMPARATOR
Intervention: IFA during pregnancy only
Number of subjects: 1151
Study 28698916 — intervention group
Group type: COMPARATOR
Intervention: MMN during pregnancy and for 6 months postpartum
Number of subjects: 1151
Study 27446944 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing assisted‐design operation (Group A)
Number of subjects: 30
Study 27446944 — intervention group
Group type: COMPARATOR
Intervention: No 3D printing assisted‐design (Group B)
Number of subjects: 30
Study 25673568 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 0
Study 25673568 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 0
Study 25673568 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 0
Study 25673568 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin acid
Number of subjects: 0
Study 25673568 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in SLCO1B1 and ABCG2
Number of subjects: 0
Study 25673568 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type alleles for SLCO1B1 and ABCG2
Number of subjects: 0
Study 24119202 — intervention group
Group type: EXPERIMENTAL
Intervention: Bixalomer (BXL)
Number of subjects: 28
Study 24119202 — intervention group
Group type: COMPARATOR
Intervention: Control (not treated with sevelamer hydrochloride)
Number of subjects: 28
Study 19436941 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 4995
Study 19436941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4995
Study 18541123 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (5-25 microg/kg, s.c. abdomen, morning)
Number of subjects: 24
Study 18541123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16316966 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-metal stenting
Number of subjects: 220
Study 16316966 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive bypass surgery
Number of subjects: 220
Study 12550805 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskus
Number of subjects: 45
Study 12550805 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 45
Study 10510104 — intervention group
Group type: EXPERIMENTAL
Intervention: J stent inserted before extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 400
Study 10510104 — intervention group
Group type: COMPARATOR
Intervention: No J stent inserted before extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 400
Study 10510104 — intervention group
Group type: EXPERIMENTAL
Intervention: J stent inserted before ESWL
Number of subjects: 400
Study 10510104 — intervention group
Group type: COMPARATOR
Intervention: No J stent inserted before ESWL
Number of subjects: 400
Study 8815556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepartricin at a dose of 150,000 U, administered once a day in the evening for 6 months
Number of subjects: 0
Study 8815556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1716079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell separator
Number of subjects: 30
Study 1716079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration
Number of subjects: 30
Study 1716079 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 30
Study 1716079 — intervention group
Group type: COMPARATOR
Intervention: Control (neurosurgery)
Number of subjects: 30
Study 6524275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular oxycodone and/or metamizol (IM)
Number of subjects: 80
Study 6524275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal block with 0.5% bupivacaine (IC)
Number of subjects: 80
Study 6524275 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 4 mg (EM)
Number of subjects: 80
Study 6524275 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. infusion of fentanyl 0.54‐0.99 micrograms min‐1 + on-demand boluses of 7.2‐13.5 micrograms (ODAC)
Number of subjects: 80
Study 30969976 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped Classroom (FC)
Number of subjects: 137
Study 30969976 — intervention group
Group type: COMPARATOR
Intervention: Lecture-Based Learning (LBL)
Number of subjects: 137
Study 28265180 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise on a treadmill initiated 72 hours after admission
Number of subjects: 11
Study 27129139 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy performed twice a week
Number of subjects: 24
Study 27129139 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 24
Study 25112009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 microg x kg(‐1) x h(‐1)) and remifentanil (0.05 microg x kg(‐1) x min(‐1))
Number of subjects: 50
Study 25112009 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia by lidocaine (1%) combined with midazolam (0.04 mg/kg) intravenous sedation
Number of subjects: 50
Study 21567655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 0
Study 21567655 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 0
Study 21567655 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 0
Study 19618315 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/d combined with aspirin 100 mg/d
Number of subjects: 60
Study 19618315 — intervention group
Group type: COMPARATOR
Intervention: Continuation of aspirin 100 mg/d
Number of subjects: 60
Study 19332730 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg
Number of subjects: 168
Study 19332730 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib 250 mg
Number of subjects: 168
Study 16115690 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator's Assessment Questionnaire (IAQ)
Number of subjects: 300
Study 12106935 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg orally twice daily) with 0.45% saline intravenously (group A)
Number of subjects: 183
Study 12106935 — intervention group
Group type: COMPARATOR
Intervention: 0.45% saline intravenously alone (group B)
Number of subjects: 183
Study 10433420 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft surface (ksurf = 21.3 kN m(‐1))
Number of subjects: 6
Study 10433420 — intervention group
Group type: COMPARATOR
Intervention: Hard surface (ksurf = 533 kN m(‐1))
Number of subjects: 6
Study 7674203 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle splitting incision
Number of subjects: 0
Study 7674203 — intervention group
Group type: COMPARATOR
Intervention: Muscle dividing incision
Number of subjects: 0
Study 2206783 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10‐40 mg once daily
Number of subjects: 128
Study 2206783 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard 10‐40 mg twice daily
Number of subjects: 128
Study 2206783 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5‐50 mg once daily (added for inadequate responders)
Number of subjects: 128
Study 2206783 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 128
Study 2206783 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 128
Study 7328680 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of arousal
Number of subjects: 30
Study 7328680 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital pulse amplitude
Number of subjects: 30
Study 7328680 — intervention group
Group type: EXPERIMENTAL
Intervention: Time above a criterion level of increased vasocongestion
Number of subjects: 30
Study 7328680 — intervention group
Group type: EXPERIMENTAL
Intervention: Erotic tape recordings
Number of subjects: 30
Study 7328680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fantasy
Number of subjects: 30
Study 7328680 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase of the menstrual cycle
Number of subjects: 30
Study 31930892 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Shaoze (SI 1)
Number of subjects: 62
Study 31930892 — intervention group
Group type: COMPARATOR
Intervention: Control group (Electroacupuncture at Shangyang (LI 1))
Number of subjects: 62
Study 30744606 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention with health coaching and mobile health support (including a physical activity information booklet, one face-to-face session, and 12 telephone sessions, supported by an internet-based application and an activity tracker).
Number of subjects: 68
Study 30744606 — intervention group
Group type: COMPARATOR
Intervention: Standard care (physical activity information booklet and advice to stay active).
Number of subjects: 68
Study 28444355 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low calorie diet with regular review (n = 30)
Number of subjects: 60
Study 28444355 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding (n = 30)
Number of subjects: 60
Study 27611077 — intervention group
Group type: EXPERIMENTAL
Intervention: Brincidofovir 200 mg loading dose on day 0, followed by 100 mg on days 3, 7, 10, and 14 (bodyweight-adjusted for patients <50 kg).
Number of subjects: 4
Study 24414742 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise protection group
Number of subjects: 83
Study 24414742 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group
Number of subjects: 83
Study 24414742 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 21926599 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion for blood glucose control to 80-110 mg/dL
Number of subjects: 0
Study 21926599 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose management (insulin administered only when glucose levels rose above 215 mg/dL)
Number of subjects: 0
Study 21926599 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 0
Study 21926599 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 19950091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 47
Study 17323226 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 evoked potential in SD patients
Number of subjects: 25
Study 17323226 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (25 individuals)
Number of subjects: 25
Study 15310081 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 to 100 mg/d
Number of subjects: 30
Study 15310081 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 to 160 mg/d
Number of subjects: 30
Study 11557917 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 596
Study 9753850 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum tocopherols levels in coronary artery disease patients
Number of subjects: 40
Study 9753850 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 40
Study 7811043 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (528 mg, 30 ml of Pepto-Bismol)
Number of subjects: 12
Study 7811043 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (750 mg)
Number of subjects: 12
Study 3290706 — intervention group
Group type: EXPERIMENTAL
Intervention: CR4-Sinemet (twice daily)
Number of subjects: 36
Study 3290706 — intervention group
Group type: COMPARATOR
Intervention: CR4-Sinemet
Number of subjects: 36
Study 16225491 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 10
Study 16225491 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with gastro-oesophageal reflux disease
Number of subjects: 10
Study 31241510 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV Stigma-reduction through Education, Empowerment, and Research (SEERs) Project
Number of subjects: 641
Study 28650919 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 25648
Study 28650919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25648
Study 28650919 — intervention group
Group type: EXPERIMENTAL
Intervention: HYSUD model
Number of subjects: 25648
Study 25382074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection (IVBI) 1.25 mg at baseline and pro re nata based on ME presence; follow-up for 12 months.
Number of subjects: 35
Study 25382074 — intervention group
Group type: COMPARATOR
Intervention: Subthreshold grid laser treatment (SGLT) administered once; follow-up for 12 months.
Number of subjects: 35
Study 23441791 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser assisted pocket therapy (ELAPT)
Number of subjects: 15
Study 23441791 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 15
Study 23441791 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (ELAPT and OFD)
Number of subjects: 15
Study 21855969 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine treatment
Number of subjects: 282
Study 18479284 — intervention group
Group type: COMPARATOR
Intervention: AngioSeal VIP
Number of subjects: 401
Study 18479284 — intervention group
Group type: EXPERIMENTAL
Intervention: StarClose
Number of subjects: 401
Study 16787799 — intervention group
Group type: EXPERIMENTAL
Intervention: Boehler's angle (BA)
Number of subjects: 133
Study 16787799 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical angle of Gissane (CAG)
Number of subjects: 133
Study 16787799 — intervention group
Group type: COMPARATOR
Intervention: Emergency physicians diagnosing without angle measurements
Number of subjects: 133
Study 14603093 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of benzathine penicillin, azithromycin, and cefixime
Number of subjects: 186
Study 14603093 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of cefixime and 3 doses of azithromycin given biweekly
Number of subjects: 186
Study 11164425 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg bezafibrate once daily for 6 weeks
Number of subjects: 18
Study 11164425 — intervention group
Group type: COMPARATOR
Intervention: Control VLDL
Number of subjects: 18
Study 9342067 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (300 microg subcutaneously daily for 1 week, then 150 microg subcutaneously two times weekly for 11 weeks)
Number of subjects: 244
Study 9342067 — intervention group
Group type: COMPARATOR
Intervention: Non-treated controls
Number of subjects: 244
Study 9342067 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (treated group)
Number of subjects: 244
Study 8210831 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 0
Study 8210831 — intervention group
Group type: COMPARATOR
Intervention: Cox model
Number of subjects: 0
Study 2870732 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 141,292 200 mg
Number of subjects: 13
Study 2870732 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 141,292 400 mg
Number of subjects: 13
Study 2870732 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg
Number of subjects: 13
Study 2870732 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 13
Study 30133950 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA air cleaner
Number of subjects: 0
Study 30133950 — intervention group
Group type: COMPARATOR
Intervention: Placebo 'dummy' air cleaner
Number of subjects: 0
Study 26569624 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin, 3mg/d for 4 weeks
Number of subjects: 73
Study 26569624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 25721770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-containing sequential therapy
Number of subjects: 212
Study 25721770 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin-containing sequential therapy
Number of subjects: 212
Study 23715567 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapy (n = 122)
Number of subjects: 182
Study 23715567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 60)
Number of subjects: 182
Study 20860413 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (3.75 g/day)
Number of subjects: 260
Study 20860413 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam plus low-dose statin or niacin
Number of subjects: 260
Study 20860413 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (1.5 g/day to 3.75 g/day)
Number of subjects: 260
Study 18090355 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoadsorption using CytoSorb for 4 hours
Number of subjects: 8
Study 18090355 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study 15940147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 22
Study 15940147 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-methasone-17-valerate (BMV) cream 0.1%
Number of subjects: 22
Study 15940147 — intervention group
Group type: COMPARATOR
Intervention: Matching vehicle cream
Number of subjects: 22
Study 12635579 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled heparin
Number of subjects: 23
Study 12635579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10950768 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 27
Study 9088806 — intervention group
Group type: EXPERIMENTAL
Intervention: OLITA program (Outpatient Long‐term Intensive Therapy for Alcoholics)
Number of subjects: 30
Study 1534047 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily in the morning for seven days
Number of subjects: 8
Study 1534047 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily in the evening for seven days
Number of subjects: 8
Study 1534047 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (morning and evening dosing)
Number of subjects: 8
Study 3996470 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate
Number of subjects: 18
Study 3996470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30736761 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative shoulder exercise treatment (not specified dosage or duration)
Number of subjects: 56
Study 30736761 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving non-operative shoulder treatment)
Number of subjects: 56
Study 28945646 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric contact lenses (TCL)
Number of subjects: 60
Study 28945646 — intervention group
Group type: COMPARATOR
Intervention: Soft spherical contact lenses (SCL)
Number of subjects: 60
Study 25241755 — intervention group
Group type: EXPERIMENTAL
Intervention: T-PEMF once daily (active dose in the morning and sham in the afternoon)
Number of subjects: 65
Study 25241755 — intervention group
Group type: EXPERIMENTAL
Intervention: T-PEMF twice daily (active dose both morning and afternoon)
Number of subjects: 65
Study 23143424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hebrew version of Pelvic Floor Distress Inventory
Number of subjects: 56
Study 23143424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hebrew version of Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire
Number of subjects: 56
Study 23143424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hebrew version of Urgency, Severity and Impact Questionnaire
Number of subjects: 56
Study 23143424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hebrew version of all questionnaires (refilled after 2 weeks)
Number of subjects: 56
Study 19694925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 372
Study 19694925 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 372
Study 18931219 — intervention group
Group type: EXPERIMENTAL
Intervention: NMBAS-guided rocuronium administration
Number of subjects: 73
Study 18931219 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 73
Study 11707843 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCH chemotherapy (etoposide/doxorubicin/vincristine/cyclophosphamide/prednisone)
Number of subjects: 93
Study 11707843 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCH chemotherapy
Number of subjects: 93
Study 9203934 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily for four weeks
Number of subjects: 18
Study 9203934 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 18
Study 9203934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7692755 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy for recurrent malignant neoplasia (pure yolk sac tumor or teratoma with yolk sac elements)
Number of subjects: 6
Study 7692755 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic examination of original tumors
Number of subjects: 6
Study 3114808 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg alprazolam PO daily as 2 mg bid
Number of subjects: 16
Study 3114808 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg qid
Number of subjects: 16
Study 3114808 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg each hour
Number of subjects: 16
Study 3114808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29766330 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 60
Study 29766330 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment alone (Er group)
Number of subjects: 60
Study 29766330 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with Nd:YAG and Er:YAG lasers (NdErNd group)
Number of subjects: 60
Study 28162931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Staged multicomponent tailored behavioral interventions (e.g., electronic monitoring feedback, motivational interviewing)
Number of subjects: 205
Study 28162931 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - Usual care
Number of subjects: 205
Study 28162931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 205